We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MULT3:BMFBOVESPAMultiplan Empreendimentos Imobiliarios SA Analysis

Data as of 2026-03-17 - not real-time

R$30.65

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Multiplan is trading around 30.65 BRL, which sits below its 20‑day SMA of roughly 33.1 but above the 200‑day SMA of 28.5, indicating a short‑term pullback within a longer‑term uptrend. The RSI at 38 suggests modest downside momentum, while the MACD shows a bearish signal with the histogram turning negative. Volume has been decreasing, adding pressure to the price, and the technical outlook points to a near‑term correction. On the valuation side, the DCF‑derived fair value of about 20.85 BRL places the current price well above intrinsic estimates, implying the stock is overvalued relative to fundamentals. Nevertheless, the dividend yield of 4% and a payout ratio near 44% make the dividend component attractive, and the company’s strong operating margins (>70%) and solid free cash flow support dividend sustainability.
Fundamentally, revenue has slipped by roughly 3.7% year‑over‑year, yet profit margins remain robust at over 40%, and ROE is near 19%. The balance sheet is heavily leveraged, with a debt‑to‑equity ratio close to 87%, though cash flow generation appears sufficient to service debt. Compared with an industry average P/E of 32.8, MULT3’s P/E of 13 is low, but the high debt and overvaluation by DCF temper optimism. The stock’s low beta (≈0.34) suggests limited price volatility relative to the market, while the 30‑day volatility of nearly 30% signals notable price swings. Overall, the blend of attractive dividend yield, solid margins, and overvaluation creates a nuanced picture for investors.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • price below 20‑day SMA
  • bearish MACD signal
  • decreasing volume trend

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • attractive 4% dividend yield
  • strong operating margins and cash flow
  • valuation gap between market price and DCF fair value

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • low beta indicating stability
  • high dividend sustainability
  • elevated debt level requiring monitoring

Key Metrics & Analysis

Financial Health

Revenue Growth-3.70%
Profit Margin41.66%
P/E Ratio13.3
ROE19.11%
ROA9.09%
Debt/Equity86.86
P/B Ratio2.4
Op. Cash FlowR$1.5B
Free Cash FlowR$1.1B
Industry P/E32.8

Technical Analysis

TrendBullish
RSI38.6
SupportR$0.00
ResistanceR$35.96
MA 20R$33.11
MA 50R$31.70
MA 200R$28.51
MACDBearish
VolumeDecreasing
Fear & Greed Index79.39

Valuation

Fair ValueR$20.85
Target PriceR$36.29
Upside/Downside18.41%
GradeOvervalued
TypeValue
Dividend Yield4.00%

Risk Assessment

Beta0.34
Volatility29.50%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.